Vaxcyte, Inc. Profile Avatar - Palmy Investing

Vaxcyte, Inc.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in …

Biotechnology
US, San Carlos [HQ]
Strategy & Leadership

Mergers & Acquisitions Beta

M&A Deals · Breakdown

Vaxcyte, Inc. has no acquisition track records yet.

M&A Deals · History

Vaxcyte, Inc. has no acquisition track records yet.

M&A Deals · Within Industry

No current deals within Biotechnology Industry.

M&A Deals · Latest

Act, dont react; Track the most urgent M&A deals across all industries

Details
Owens Corning
Debt
Agg. Maximum Price
$373,155,000.00
Details
?
Equity
Agg. Maximum Price
$n/a
Details
?
Equity
Agg. Maximum Price
$4,221.65
?
Details
?
Equity
Agg. Maximum Price
$2,264,484.00
Details
United Bankshares, Inc.
Equity
Agg. Maximum Price
$206,633,909.86
?
Details
?
Equity
Agg. Maximum Price
$381.73
Details
?
Equity
Agg. Maximum Price
$7,657,428.54
Details
Icahn Enterprises L.P.
Debt
Agg. Maximum Price
$700,000,000.00
?
Details
?
Equity
Agg. Maximum Price
$19,377,844.50
Details
Corebridge Financial, Inc.
Debt
Agg. Maximum Price
$500,000,000.00
End of PCVX's Analysis
CIK: 1649094 CUSIP: 92243G108 ISIN: US92243G1085 LEI: - UEI: -
Secondary Listings
PCVX has no secondary listings inside our databases.